2026 Q2 -tulosraportti
13 päivää sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenGBS = BLOCKBUSTER MARKET OPPORTUNITY 1. Medical potential: 8.5/10 GBS is an acute autoimmune disease where treatment must be initiated quickly. Today's standard treatment (IVIg or plasma exchange) helps many patients, but recovery can still be slow. Imlifidase has a unique mechanism of action: * It breaks down IgG antibodies within hours. * If IgG drives the disease, rapid elimination can provide a biological advantage compared to treatments that act more slowly. It is a strong scientific hypothesis. 2. Clinical data: 8/10 Phase II data is unusually impressive: * Median 16 days to independent walking. * Approximately 6 weeks faster recovery than historical IVIg controls. * Clear improvement already after one week. At the same time, it is important to remember that: * the study was small, * it was open-label, * the control was historical. This means that the effect may be overestimated compared to what a randomized study shows. 3. Competition: 7/10 The biggest competitor is tanruprubart (Annexo), which in a large randomized Phase III study showed: * achieved primary endpoint, * approximately 31 days earlier independent walking, * robust improvements in several secondary outcomes. Tanruprubart therefore has a clear evidence advantage today. But imlifidase may still prove to provide a greater effect if Phase III confirms the Phase II results. 4. Regulatory risk: 6/10 This is the biggest uncertainty. If FDA accepts Hansa's proposed registration-enabling study design, the regulatory risk significantly decreases. But after that, the biggest challenge remains: to show effect in a randomized study. It is only then that the market is likely to properly re-evaluate the project. 5. Commercial potential The commercial potential for imlifidase in GBS primarily depends on how many patients are treated and what price the drug receives after a possible approval. Hansa estimates that approximately 14,000 patients in the USA and Europe could be eligible for treatment each year. If the price is set at 50,000 USD per treatment, this corresponds to a possible annual turnover of around 700 million USD. At a price of 100,000 USD, the potential increases to approximately 1.4 billion USD, and at 150,000 USD per treatment, the theoretical turnover amounts to around 2.1 billion USD. However, this should be seen as illustrative examples and not as forecasts. Actual sales will depend on several factors, including the results of the registration-enabling study, regulatory approvals, pricing, reimbursement decisions from healthcare systems, and how large a market share imlifidase can capture in competition with established treatments and new drugs like tanruprubart. If imlifidase can confirm the strong Phase II results in a randomized Phase III study, there is therefore a realistic possibility that the drug could reach annual sales in the billion-dollar range. This is also why the GBS program is considered one of Hansa Biopharma's most important value drivers in the coming years. 6. What the market is likely looking at The most important value drivers going forward are: 1. FDA's decision on study design. 2. Start of the registration-enabling study. 3. Potential partnerships 4. The first signals from the pivotal study. Overall assessment Strengths * Very strong biological rationale. * Phase II data with unusually large observed effect. * Significant commercial potential if results are confirmed. Weaknesses * The crucial Phase III evidence is missing. * Competitor already has stronger randomized data. * High clinical and regulatory risk until a pivotal study has been conducted.
Although it is very clear, I think one should state when it is an AI-“analysis”/review - I think that is good style.- ·3 päivää sittenSince Thursday, American investors have started buying the stock via OTCPK under the ticker HNSBF. Volumes are still limited, but already clearly higher than normal. At the same time, statistics show that the sell side largely consists of short positions, likely from a Market Maker. If the purchases continue and the stock gets a technical breakout, the dynamic can change quickly. My experience is that breakouts are often followed by sharply increased volumes. If the Market Maker then does not increase their short interest, they may instead be forced to buy shares on the Swedish market to meet demand. It will therefore be extra interesting to follow the development in the coming trading days. My opinion and not advice.Conclusion I would describe Hansa's GBS program as a high-risk, high-potential project. If the registrational study confirms a large part of the Phase II effect, the project could become very valuable. If, however, the effect is significantly smaller in a randomized study, there is a risk of a significantly lower commercial potential. My overall assessment is that the probability of clinical success is higher than the average for drug development, thanks to the strong biological mechanism and the promising Phase II results. At the same time, the uncertainty is still large enough that the outcome of the pivotal study will be the single most important factor for the project's future value. Tanruprubart has the stronger evidence, while imlifidase has the stronger effect signal. In a large randomized Phase III study, Tanruprubart showed a 31 days shorter time to independent ambulation (median 56 vs 87 days), achieved its primary endpoint, and improved several important clinical outcomes. In a smaller Phase II study, Imlifidase showed a median of only 16 days to independent ambulation and an estimated improvement of approximately six weeks compared to a historical IVIg-treated control cohort. This is a larger observed effect, but the results come from an open-label study without a randomized control group. The conclusion is therefore that imlifidase appears to be able to provide a greater clinical effect, but this needs to be confirmed in a randomized Phase III study before the results can be compared at the same level of evidence as tanruprubart. My assessment is therefore that the realistic commercial potential for imlifidase in GBS could be in the order of 1–2 billion USD annually, if the drug shows convincing Phase III data and gains widespread use. This is higher than today's market because a more effective drug can expand market value, not just take shares from existing treatments. My opinion and not advice. Sources https://annexonbio.com/wp-content/uploads/2025/04/AAN-GBS-02-Study-Encore-Presentation_Final.pdfhttps://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-meddelar-positiva-fullstandiga-resultat-fran-fas-2-studien-15-hmedides-09-samt-jamforande-analys-av-imlifidase-hos-patienter-med-guillain-barres-syndrom/https://ir.annexonbio.com/static-files/4c2d3860-14ce-4aef-9b55-fe6ed80ff942
- ·3 päivää sittenMedical breakthrough allows kidney transplant for patient with zero options The article from July 30 2026 should be positive for Imlifidase. The article describes a patient who was considered to have “zero options” due to extremely high levels of antibodies against donors. Researchers used an advanced immunotherapy to significantly reduce these antibodies and enable a kidney transplant. The treatment appears to be based on a more long-term “reprogramming” of the immune system, rather than a rapid breakdown of antibodies. For Imlifidase, I would assess the news as predominantly positive. It shows that: 1 the need for treatment for highly sensitized patients is great, 2 research in the field is very active. 3 the transplantation field is increasingly focusing on desensitization, 4 Imlifidase receives indirect confirmation that this is an important clinical area. The biggest risk for Imlifidase in the very long term is if cell therapies become simple, cheap, and can be widely used before transplantation. But with today's knowledge, these techniques appear to be complements rather than direct replacements. https://www.news-medical.net/news/20260730/Medical-breakthrough-allows-kidney-transplant-for-patient-with-zero-options.aspx
- ·3 päivää sittenMy analysis of the situation Today's bullish hammer appears to have caught the bears in a classic bear trap. The strong close, together with high volume, provides clear confirmation that the buyers have taken control. Now, 35.74 is the decisive level. A breakout there would confirm a powerful bullish flag and open up for a significantly stronger rally. As long as the technical picture holds, momentum appears to be on the bulls' side. My opinion and not advice, 📈👇
It could well be starting to look like a Gap Close - if no good news comes, I'm unsure if we will bottom out at the support 30 or go all the way down and hit a previous bottom around 25-26. I remain positive on the case
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
13 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenGBS = BLOCKBUSTER MARKET OPPORTUNITY 1. Medical potential: 8.5/10 GBS is an acute autoimmune disease where treatment must be initiated quickly. Today's standard treatment (IVIg or plasma exchange) helps many patients, but recovery can still be slow. Imlifidase has a unique mechanism of action: * It breaks down IgG antibodies within hours. * If IgG drives the disease, rapid elimination can provide a biological advantage compared to treatments that act more slowly. It is a strong scientific hypothesis. 2. Clinical data: 8/10 Phase II data is unusually impressive: * Median 16 days to independent walking. * Approximately 6 weeks faster recovery than historical IVIg controls. * Clear improvement already after one week. At the same time, it is important to remember that: * the study was small, * it was open-label, * the control was historical. This means that the effect may be overestimated compared to what a randomized study shows. 3. Competition: 7/10 The biggest competitor is tanruprubart (Annexo), which in a large randomized Phase III study showed: * achieved primary endpoint, * approximately 31 days earlier independent walking, * robust improvements in several secondary outcomes. Tanruprubart therefore has a clear evidence advantage today. But imlifidase may still prove to provide a greater effect if Phase III confirms the Phase II results. 4. Regulatory risk: 6/10 This is the biggest uncertainty. If FDA accepts Hansa's proposed registration-enabling study design, the regulatory risk significantly decreases. But after that, the biggest challenge remains: to show effect in a randomized study. It is only then that the market is likely to properly re-evaluate the project. 5. Commercial potential The commercial potential for imlifidase in GBS primarily depends on how many patients are treated and what price the drug receives after a possible approval. Hansa estimates that approximately 14,000 patients in the USA and Europe could be eligible for treatment each year. If the price is set at 50,000 USD per treatment, this corresponds to a possible annual turnover of around 700 million USD. At a price of 100,000 USD, the potential increases to approximately 1.4 billion USD, and at 150,000 USD per treatment, the theoretical turnover amounts to around 2.1 billion USD. However, this should be seen as illustrative examples and not as forecasts. Actual sales will depend on several factors, including the results of the registration-enabling study, regulatory approvals, pricing, reimbursement decisions from healthcare systems, and how large a market share imlifidase can capture in competition with established treatments and new drugs like tanruprubart. If imlifidase can confirm the strong Phase II results in a randomized Phase III study, there is therefore a realistic possibility that the drug could reach annual sales in the billion-dollar range. This is also why the GBS program is considered one of Hansa Biopharma's most important value drivers in the coming years. 6. What the market is likely looking at The most important value drivers going forward are: 1. FDA's decision on study design. 2. Start of the registration-enabling study. 3. Potential partnerships 4. The first signals from the pivotal study. Overall assessment Strengths * Very strong biological rationale. * Phase II data with unusually large observed effect. * Significant commercial potential if results are confirmed. Weaknesses * The crucial Phase III evidence is missing. * Competitor already has stronger randomized data. * High clinical and regulatory risk until a pivotal study has been conducted.Although it is very clear, I think one should state when it is an AI-“analysis”/review - I think that is good style.
- ·3 päivää sittenSince Thursday, American investors have started buying the stock via OTCPK under the ticker HNSBF. Volumes are still limited, but already clearly higher than normal. At the same time, statistics show that the sell side largely consists of short positions, likely from a Market Maker. If the purchases continue and the stock gets a technical breakout, the dynamic can change quickly. My experience is that breakouts are often followed by sharply increased volumes. If the Market Maker then does not increase their short interest, they may instead be forced to buy shares on the Swedish market to meet demand. It will therefore be extra interesting to follow the development in the coming trading days. My opinion and not advice.Conclusion I would describe Hansa's GBS program as a high-risk, high-potential project. If the registrational study confirms a large part of the Phase II effect, the project could become very valuable. If, however, the effect is significantly smaller in a randomized study, there is a risk of a significantly lower commercial potential. My overall assessment is that the probability of clinical success is higher than the average for drug development, thanks to the strong biological mechanism and the promising Phase II results. At the same time, the uncertainty is still large enough that the outcome of the pivotal study will be the single most important factor for the project's future value. Tanruprubart has the stronger evidence, while imlifidase has the stronger effect signal. In a large randomized Phase III study, Tanruprubart showed a 31 days shorter time to independent ambulation (median 56 vs 87 days), achieved its primary endpoint, and improved several important clinical outcomes. In a smaller Phase II study, Imlifidase showed a median of only 16 days to independent ambulation and an estimated improvement of approximately six weeks compared to a historical IVIg-treated control cohort. This is a larger observed effect, but the results come from an open-label study without a randomized control group. The conclusion is therefore that imlifidase appears to be able to provide a greater clinical effect, but this needs to be confirmed in a randomized Phase III study before the results can be compared at the same level of evidence as tanruprubart. My assessment is therefore that the realistic commercial potential for imlifidase in GBS could be in the order of 1–2 billion USD annually, if the drug shows convincing Phase III data and gains widespread use. This is higher than today's market because a more effective drug can expand market value, not just take shares from existing treatments. My opinion and not advice. Sources https://annexonbio.com/wp-content/uploads/2025/04/AAN-GBS-02-Study-Encore-Presentation_Final.pdfhttps://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-meddelar-positiva-fullstandiga-resultat-fran-fas-2-studien-15-hmedides-09-samt-jamforande-analys-av-imlifidase-hos-patienter-med-guillain-barres-syndrom/https://ir.annexonbio.com/static-files/4c2d3860-14ce-4aef-9b55-fe6ed80ff942
- ·3 päivää sittenMedical breakthrough allows kidney transplant for patient with zero options The article from July 30 2026 should be positive for Imlifidase. The article describes a patient who was considered to have “zero options” due to extremely high levels of antibodies against donors. Researchers used an advanced immunotherapy to significantly reduce these antibodies and enable a kidney transplant. The treatment appears to be based on a more long-term “reprogramming” of the immune system, rather than a rapid breakdown of antibodies. For Imlifidase, I would assess the news as predominantly positive. It shows that: 1 the need for treatment for highly sensitized patients is great, 2 research in the field is very active. 3 the transplantation field is increasingly focusing on desensitization, 4 Imlifidase receives indirect confirmation that this is an important clinical area. The biggest risk for Imlifidase in the very long term is if cell therapies become simple, cheap, and can be widely used before transplantation. But with today's knowledge, these techniques appear to be complements rather than direct replacements. https://www.news-medical.net/news/20260730/Medical-breakthrough-allows-kidney-transplant-for-patient-with-zero-options.aspx
- ·3 päivää sittenMy analysis of the situation Today's bullish hammer appears to have caught the bears in a classic bear trap. The strong close, together with high volume, provides clear confirmation that the buyers have taken control. Now, 35.74 is the decisive level. A breakout there would confirm a powerful bullish flag and open up for a significantly stronger rally. As long as the technical picture holds, momentum appears to be on the bulls' side. My opinion and not advice, 📈👇It could well be starting to look like a Gap Close - if no good news comes, I'm unsure if we will bottom out at the support 30 or go all the way down and hit a previous bottom around 25-26. I remain positive on the case
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
2026 Q2 -tulosraportti
13 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenGBS = BLOCKBUSTER MARKET OPPORTUNITY 1. Medical potential: 8.5/10 GBS is an acute autoimmune disease where treatment must be initiated quickly. Today's standard treatment (IVIg or plasma exchange) helps many patients, but recovery can still be slow. Imlifidase has a unique mechanism of action: * It breaks down IgG antibodies within hours. * If IgG drives the disease, rapid elimination can provide a biological advantage compared to treatments that act more slowly. It is a strong scientific hypothesis. 2. Clinical data: 8/10 Phase II data is unusually impressive: * Median 16 days to independent walking. * Approximately 6 weeks faster recovery than historical IVIg controls. * Clear improvement already after one week. At the same time, it is important to remember that: * the study was small, * it was open-label, * the control was historical. This means that the effect may be overestimated compared to what a randomized study shows. 3. Competition: 7/10 The biggest competitor is tanruprubart (Annexo), which in a large randomized Phase III study showed: * achieved primary endpoint, * approximately 31 days earlier independent walking, * robust improvements in several secondary outcomes. Tanruprubart therefore has a clear evidence advantage today. But imlifidase may still prove to provide a greater effect if Phase III confirms the Phase II results. 4. Regulatory risk: 6/10 This is the biggest uncertainty. If FDA accepts Hansa's proposed registration-enabling study design, the regulatory risk significantly decreases. But after that, the biggest challenge remains: to show effect in a randomized study. It is only then that the market is likely to properly re-evaluate the project. 5. Commercial potential The commercial potential for imlifidase in GBS primarily depends on how many patients are treated and what price the drug receives after a possible approval. Hansa estimates that approximately 14,000 patients in the USA and Europe could be eligible for treatment each year. If the price is set at 50,000 USD per treatment, this corresponds to a possible annual turnover of around 700 million USD. At a price of 100,000 USD, the potential increases to approximately 1.4 billion USD, and at 150,000 USD per treatment, the theoretical turnover amounts to around 2.1 billion USD. However, this should be seen as illustrative examples and not as forecasts. Actual sales will depend on several factors, including the results of the registration-enabling study, regulatory approvals, pricing, reimbursement decisions from healthcare systems, and how large a market share imlifidase can capture in competition with established treatments and new drugs like tanruprubart. If imlifidase can confirm the strong Phase II results in a randomized Phase III study, there is therefore a realistic possibility that the drug could reach annual sales in the billion-dollar range. This is also why the GBS program is considered one of Hansa Biopharma's most important value drivers in the coming years. 6. What the market is likely looking at The most important value drivers going forward are: 1. FDA's decision on study design. 2. Start of the registration-enabling study. 3. Potential partnerships 4. The first signals from the pivotal study. Overall assessment Strengths * Very strong biological rationale. * Phase II data with unusually large observed effect. * Significant commercial potential if results are confirmed. Weaknesses * The crucial Phase III evidence is missing. * Competitor already has stronger randomized data. * High clinical and regulatory risk until a pivotal study has been conducted.Although it is very clear, I think one should state when it is an AI-“analysis”/review - I think that is good style.
- ·3 päivää sittenSince Thursday, American investors have started buying the stock via OTCPK under the ticker HNSBF. Volumes are still limited, but already clearly higher than normal. At the same time, statistics show that the sell side largely consists of short positions, likely from a Market Maker. If the purchases continue and the stock gets a technical breakout, the dynamic can change quickly. My experience is that breakouts are often followed by sharply increased volumes. If the Market Maker then does not increase their short interest, they may instead be forced to buy shares on the Swedish market to meet demand. It will therefore be extra interesting to follow the development in the coming trading days. My opinion and not advice.Conclusion I would describe Hansa's GBS program as a high-risk, high-potential project. If the registrational study confirms a large part of the Phase II effect, the project could become very valuable. If, however, the effect is significantly smaller in a randomized study, there is a risk of a significantly lower commercial potential. My overall assessment is that the probability of clinical success is higher than the average for drug development, thanks to the strong biological mechanism and the promising Phase II results. At the same time, the uncertainty is still large enough that the outcome of the pivotal study will be the single most important factor for the project's future value. Tanruprubart has the stronger evidence, while imlifidase has the stronger effect signal. In a large randomized Phase III study, Tanruprubart showed a 31 days shorter time to independent ambulation (median 56 vs 87 days), achieved its primary endpoint, and improved several important clinical outcomes. In a smaller Phase II study, Imlifidase showed a median of only 16 days to independent ambulation and an estimated improvement of approximately six weeks compared to a historical IVIg-treated control cohort. This is a larger observed effect, but the results come from an open-label study without a randomized control group. The conclusion is therefore that imlifidase appears to be able to provide a greater clinical effect, but this needs to be confirmed in a randomized Phase III study before the results can be compared at the same level of evidence as tanruprubart. My assessment is therefore that the realistic commercial potential for imlifidase in GBS could be in the order of 1–2 billion USD annually, if the drug shows convincing Phase III data and gains widespread use. This is higher than today's market because a more effective drug can expand market value, not just take shares from existing treatments. My opinion and not advice. Sources https://annexonbio.com/wp-content/uploads/2025/04/AAN-GBS-02-Study-Encore-Presentation_Final.pdfhttps://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-meddelar-positiva-fullstandiga-resultat-fran-fas-2-studien-15-hmedides-09-samt-jamforande-analys-av-imlifidase-hos-patienter-med-guillain-barres-syndrom/https://ir.annexonbio.com/static-files/4c2d3860-14ce-4aef-9b55-fe6ed80ff942
- ·3 päivää sittenMedical breakthrough allows kidney transplant for patient with zero options The article from July 30 2026 should be positive for Imlifidase. The article describes a patient who was considered to have “zero options” due to extremely high levels of antibodies against donors. Researchers used an advanced immunotherapy to significantly reduce these antibodies and enable a kidney transplant. The treatment appears to be based on a more long-term “reprogramming” of the immune system, rather than a rapid breakdown of antibodies. For Imlifidase, I would assess the news as predominantly positive. It shows that: 1 the need for treatment for highly sensitized patients is great, 2 research in the field is very active. 3 the transplantation field is increasingly focusing on desensitization, 4 Imlifidase receives indirect confirmation that this is an important clinical area. The biggest risk for Imlifidase in the very long term is if cell therapies become simple, cheap, and can be widely used before transplantation. But with today's knowledge, these techniques appear to be complements rather than direct replacements. https://www.news-medical.net/news/20260730/Medical-breakthrough-allows-kidney-transplant-for-patient-with-zero-options.aspx
- ·3 päivää sittenMy analysis of the situation Today's bullish hammer appears to have caught the bears in a classic bear trap. The strong close, together with high volume, provides clear confirmation that the buyers have taken control. Now, 35.74 is the decisive level. A breakout there would confirm a powerful bullish flag and open up for a significantly stronger rally. As long as the technical picture holds, momentum appears to be on the bulls' side. My opinion and not advice, 📈👇It could well be starting to look like a Gap Close - if no good news comes, I'm unsure if we will bottom out at the support 30 or go all the way down and hit a previous bottom around 25-26. I remain positive on the case
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt